[1]
Devaud N, Vornicova O, Abdul Razak AR, Khalili K, Demicco EG, Mitric C, Bernardini MQ, Gladdy RA. Leiomyosarcoma: Current Clinical Management and Future Horizons. Surgical oncology clinics of North America. 2022 Jul:31(3):527-546. doi: 10.1016/j.soc.2022.03.011. Epub
[PubMed PMID: 35715148]
[2]
Serrano C, George S. Leiomyosarcoma. Hematology/oncology clinics of North America. 2013 Oct:27(5):957-74. doi: 10.1016/j.hoc.2013.07.002. Epub 2013 Aug 26
[PubMed PMID: 24093170]
[3]
Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Desai A, Gladdy RA, Gonzalez R, Gyorki DE, Fairweather M, van Houdt WJ, Stoeckle E, Park JB, Albertsmeier M, Nessim C, Cardona K, Fiore M, Hayes A, Tzanis D, Skoczylas J, Ford SJ, Ng D, Mullinax JE, Snow H, Haas RL, Callegaro D, Smith MJ, Bouhadiba T, Stacchiotti S, Jones RL, DeLaney T, Roland CL, Raut CP, Gronchi A, Transatlantic Australasian RPS Working Group (TARPSWG). Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. Annals of surgical oncology. 2021 Nov:28(12):7873-7888. doi: 10.1245/s10434-021-09654-z. Epub 2021 Apr 14
[PubMed PMID: 33852100]
Level 3 (low-level) evidence
[4]
Adam MA, Moris D, Behrens S, Nussbaum DP, Jawitz O, Turner M, Lidsky M, Blazer D 3rd. Hospital Volume Threshold for the Treatment of Retroperitoneal Sarcoma. Anticancer research. 2019 Apr:39(4):2007-2014. doi: 10.21873/anticanres.13311. Epub
[PubMed PMID: 30952744]
[5]
Robinson E, Neugut AI, Wylie P. Clinical aspects of postirradiation sarcomas. Journal of the National Cancer Institute. 1988 Apr 20:80(4):233-40
[PubMed PMID: 3280809]
[6]
George S, Serrano C, Hensley ML, Ray-Coquard I. Soft Tissue and Uterine Leiomyosarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Jan 10:36(2):144-150. doi: 10.1200/JCO.2017.75.9845. Epub 2017 Dec 8
[PubMed PMID: 29220301]
[7]
Guo X, Jo VY, Mills AM, Zhu SX, Lee CH, Espinosa I, Nucci MR, Varma S, Forgó E, Hastie T, Anderson S, Ganjoo K, Beck AH, West RB, Fletcher CD, van de Rijn M. Clinically Relevant Molecular Subtypes in Leiomyosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Aug 1:21(15):3501-11. doi: 10.1158/1078-0432.CCR-14-3141. Epub 2015 Apr 20
[PubMed PMID: 25896974]
[8]
Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: A review of the literature and update on management options. Gynecologic oncology. 2018 Dec:151(3):562-572. doi: 10.1016/j.ygyno.2018.09.010. Epub 2018 Sep 21
[PubMed PMID: 30244960]
[9]
Cui RR, Wright JD, Hou JY. Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome. BJOG : an international journal of obstetrics and gynaecology. 2017 Jun:124(7):1028-1037. doi: 10.1111/1471-0528.14579. Epub 2017 Apr 1
[PubMed PMID: 28128524]
Level 3 (low-level) evidence
[10]
Cancer Genome Atlas Research Network. Electronic address: elizabeth.demicco@sinaihealthsystem.ca, Cancer Genome Atlas Research Network. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell. 2017 Nov 2:171(4):950-965.e28. doi: 10.1016/j.cell.2017.10.014. Epub
[PubMed PMID: 29100075]
[11]
Martin-Liberal J. Leiomyosarcoma: Principles of management. Intractable & rare diseases research. 2013 Nov:2(4):127-9. doi: 10.5582/irdr.2013.v2.4.127. Epub
[PubMed PMID: 25343116]
[12]
Ip PP, Cheung AN. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential. Best practice & research. Clinical obstetrics & gynaecology. 2011 Dec:25(6):691-704. doi: 10.1016/j.bpobgyn.2011.07.003. Epub 2011 Aug 23
[PubMed PMID: 21865091]
[13]
Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. The American journal of surgical pathology. 1994 Jun:18(6):535-58
[PubMed PMID: 8179071]
Level 3 (low-level) evidence
[14]
Leitao MM, Soslow RA, Nonaka D, Olshen AB, Aghajanian C, Sabbatini P, Dupont J, Hensley M, Sonoda Y, Barakat RR, Anderson S. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer. 2004 Sep 15:101(6):1455-62
[PubMed PMID: 15316901]
[15]
Demas BE, Heelan RT, Lane J, Marcove R, Hajdu S, Brennan MF. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR. American journal of roentgenology. 1988 Mar:150(3):615-20
[PubMed PMID: 3257620]
[16]
Strauss DC, Qureshi YA, Hayes AJ, Thway K, Fisher C, Thomas JM. The role of core needle biopsy in the diagnosis of suspected soft tissue tumours. Journal of surgical oncology. 2010 Oct 1:102(5):523-9. doi: 10.1002/jso.21600. Epub
[PubMed PMID: 20872955]
[17]
Narvani AA, Tsiridis E, Saifuddin A, Briggs T, Cannon S. Does image guidance improve accuracy of core needle biopsy in diagnosis of soft tissue tumours? Acta orthopaedica Belgica. 2009 Apr:75(2):239-44
[PubMed PMID: 19492564]
[18]
Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Jan:16(1):197-203
[PubMed PMID: 9440743]
Level 1 (high-level) evidence
[19]
Haas RL, Baldini EH, Chung PW, van Coevorden F, DeLaney TF. Radiation therapy in retroperitoneal sarcoma management. Journal of surgical oncology. 2018 Jan:117(1):93-98. doi: 10.1002/jso.24892. Epub 2017 Nov 22
[PubMed PMID: 29165813]
[20]
Byerly S, Chopra S, Nassif NA, Chen P, Sener SF, Eisenberg BL, Tseng WW. The role of margins in extremity soft tissue sarcoma. Journal of surgical oncology. 2016 Mar:113(3):333-8. doi: 10.1002/jso.24112. Epub 2015 Dec 10
[PubMed PMID: 26662660]
[21]
Kandel R, Coakley N, Werier J, Engel J, Ghert M, Verma S, Sarcoma Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. Surgical margins and handling of soft-tissue sarcoma in extremities: a clinical practice guideline. Current oncology (Toronto, Ont.). 2013 Jun:20(3):e247-54. doi: 10.3747/co.20.1308. Epub
[PubMed PMID: 23737694]
Level 1 (high-level) evidence
[22]
Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, Bouzaiene H, Le Péchoux C, Casali PG, Le Cesne A, Fiore M, Gronchi A. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Annals of surgical oncology. 2010 Jun:17(6):1507-14. doi: 10.1245/s10434-010-1057-5. Epub
[PubMed PMID: 20393803]
[23]
MacNeill AJ, Fiore M. Surgical morbidity in retroperitoneal sarcoma resection. Journal of surgical oncology. 2018 Jan:117(1):56-61. doi: 10.1002/jso.24902. Epub 2018 Jan 3
[PubMed PMID: 29314041]
[24]
Bonvalot S, Gronchi A, Le Péchoux C, Swallow CJ, Strauss D, Meeus P, van Coevorden F, Stoldt S, Stoeckle E, Rutkowski P, Rastrelli M, Raut CP, Hompes D, De Paoli A, Sangalli C, Honoré C, Chung P, Miah A, Blay JY, Fiore M, Stelmes JJ, Dei Tos AP, Baldini EH, Litière S, Marreaud S, Gelderblom H, Haas RL. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 2020 Oct:21(10):1366-1377. doi: 10.1016/S1470-2045(20)30446-0. Epub 2020 Sep 14
[PubMed PMID: 32941794]
Level 1 (high-level) evidence
[25]
Seagle BL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. Gynecologic oncology. 2017 Apr:145(1):61-70. doi: 10.1016/j.ygyno.2017.02.012. Epub 2017 Mar 15
[PubMed PMID: 28317559]
[26]
Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2018 Oct:143 Suppl 2():51-58. doi: 10.1002/ijgo.12613. Epub
[PubMed PMID: 30306577]
[27]
von Mehren M, Kane JM, Agulnik M, Bui MM, Carr-Ascher J, Choy E, Connelly M, Dry S, Ganjoo KN, Gonzalez RJ, Holder A, Homsi J, Keedy V, Kelly CM, Kim E, Liebner D, McCarter M, McGarry SV, Mesko NW, Meyer C, Pappo AS, Parkes AM, Petersen IA, Pollack SM, Poppe M, Riedel RF, Schuetze S, Shabason J, Sicklick JK, Spraker MB, Zimel M, Hang LE, Sundar H, Bergman MA. Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2022 Jul:20(7):815-833. doi: 10.6004/jnccn.2022.0035. Epub
[PubMed PMID: 35830886]
Level 1 (high-level) evidence
[28]
Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Mar:14(3):859-68
[PubMed PMID: 8622034]
Level 1 (high-level) evidence
[29]
Haas RL, Delaney TF, O'Sullivan B, Keus RB, Le Pechoux C, Olmi P, Poulsen JP, Seddon B, Wang D. Radiotherapy for management of extremity soft tissue sarcomas: why, when, and where? International journal of radiation oncology, biology, physics. 2012 Nov 1:84(3):572-80. doi: 10.1016/j.ijrobp.2012.01.062. Epub 2012 Apr 18
[PubMed PMID: 22520481]
[30]
Griffin AM, Dickie CI, Catton CN, Chung PW, Ferguson PC, Wunder JS, O'Sullivan B. The influence of time interval between preoperative radiation and surgical resection on the development of wound healing complications in extremity soft tissue sarcoma. Annals of surgical oncology. 2015 Sep:22(9):2824-30. doi: 10.1245/s10434-015-4631-z. Epub 2015 May 28
[PubMed PMID: 26018726]
[31]
Tiong SS, Dickie C, Haas RL, O'Sullivan B. The role of radiotherapy in the management of localized soft tissue sarcomas. Cancer biology & medicine. 2016 Sep:13(3):373-383
[PubMed PMID: 27807504]
[32]
Nussbaum DP, Rushing CN, Lane WO, Cardona DM, Kirsch DG, Peterson BL, Blazer DG 3rd. Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. The Lancet. Oncology. 2016 Jul:17(7):966-975. doi: 10.1016/S1470-2045(16)30050-X. Epub 2016 May 17
[PubMed PMID: 27210906]
Level 2 (mid-level) evidence
[33]
Gronchi A, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, Bertola G, Navarria P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorello L, Fiore M, Bruzzi P, Casali PG. Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. European journal of cancer (Oxford, England : 1990). 2014 Mar:50(4):784-92. doi: 10.1016/j.ejca.2013.11.021. Epub 2013 Dec 5
[PubMed PMID: 24316063]
[34]
Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen JJ, Coens C, Teodorovic I, Vergote I, Vermorken JB, European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). European journal of cancer (Oxford, England : 1990). 2008 Apr:44(6):808-18. doi: 10.1016/j.ejca.2008.01.019. Epub 2008 Apr 2
[PubMed PMID: 18378136]
Level 2 (mid-level) evidence
[35]
Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder C, Lhommé C, Rey A. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Apr:24(4):1099-104. doi: 10.1093/annonc/mds545. Epub 2012 Nov 8
[PubMed PMID: 23139262]
Level 1 (high-level) evidence
[36]
Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010 Oct 1:116(19):4613-21. doi: 10.1002/cncr.25350. Epub
[PubMed PMID: 20572040]
[37]
Tseng WW, Zhou S, To CA, Thall PF, Lazar AJ, Pollock RE, Lin PP, Cormier JN, Lewis VO, Feig BW, Hunt KK, Ballo MT, Patel S, Pisters PW. Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma. Cancer. 2015 Oct 15:121(20):3659-67. doi: 10.1002/cncr.29544. Epub 2015 Jul 15
[PubMed PMID: 26177983]
[38]
Grimer R, Judson I, Peake D, Seddon B. Guidelines for the management of soft tissue sarcomas. Sarcoma. 2010:2010():506182. doi: 10.1155/2010/506182. Epub 2010 May 31
[PubMed PMID: 20634933]
[39]
Loong HH, Wong KH, Tse T. Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas. ESMO open. 2018:3(Suppl 1):e000293. doi: 10.1136/esmoopen-2017-000293. Epub 2018 Jan 3
[PubMed PMID: 29333281]
Level 3 (low-level) evidence
[40]
. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet (London, England). 1997 Dec 6:350(9092):1647-54
[PubMed PMID: 9400508]
Level 1 (high-level) evidence
[41]
Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008 Aug 1:113(3):573-81. doi: 10.1002/cncr.23592. Epub
[PubMed PMID: 18521899]
Level 1 (high-level) evidence
[42]
Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Mar 1:19(5):1238-47
[PubMed PMID: 11230464]
Level 1 (high-level) evidence
[43]
Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PC, Ouali M, Marreaud S, Bramwell VH, Hohenberger P, EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. The Lancet. Oncology. 2012 Oct:13(10):1045-54. doi: 10.1016/S1470-2045(12)70346-7. Epub 2012 Sep 4
[PubMed PMID: 22954508]
Level 1 (high-level) evidence
[44]
Biau DJ, Weiss KR, Bhumbra RS, Davidson D, Brown C, Griffin A, Wunder JS, Ferguson PC. Monitoring the adequacy of surgical margins after resection of bone and soft-tissue sarcoma. Annals of surgical oncology. 2013 Jun:20(6):1858-64. doi: 10.1245/s10434-012-2863-8. Epub 2013 Jan 31
[PubMed PMID: 23370669]
[45]
Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Jul:11(7):1276-85
[PubMed PMID: 8315425]
Level 1 (high-level) evidence
[46]
Gortzak E, Azzarelli A, Buesa J, Bramwell VH, van Coevorden F, van Geel AN, Ezzat A, Santoro A, Oosterhuis JW, van Glabbeke M, Kirkpatrick A, Verweij J, E.O.R.T.C. Soft Tissue Bone Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group/Canadian Sarcoma Group. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. European journal of cancer (Oxford, England : 1990). 2001 Jun:37(9):1096-103
[PubMed PMID: 11378339]
Level 1 (high-level) evidence
[47]
Gronchi A, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M, Casali PG. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Mar:24(3):817-23. doi: 10.1093/annonc/mds501. Epub 2012 Oct 30
[PubMed PMID: 23110811]
Level 2 (mid-level) evidence
[48]
Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. The Lancet. Oncology. 2017 Jun:18(6):812-822. doi: 10.1016/S1470-2045(17)30334-0. Epub 2017 May 9
[PubMed PMID: 28499583]
Level 1 (high-level) evidence
[49]
Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nature reviews. Clinical oncology. 2014 Apr:11(4):187-202. doi: 10.1038/nrclinonc.2014.26. Epub 2014 Mar 18
[PubMed PMID: 24642677]
[50]
Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Aug 1:19(15):3483-9
[PubMed PMID: 11481354]
[51]
Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Jul 1:25(19):2755-63
[PubMed PMID: 17602081]
Level 1 (high-level) evidence
[52]
Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. The Lancet. Oncology. 2017 Oct:18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4
[PubMed PMID: 28882536]
Level 1 (high-level) evidence
[53]
Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. The oncologist. 2005 Nov-Dec:10(10):833-41
[PubMed PMID: 16314294]
[54]
Bui-Nguyen B, Ray-Coquard I, Chevreau C, Penel N, Bay JO, Coindre JM, Cupissol D, Italiano A, Bonichon F, Lotz JP, Thyss A, Jimenez M, Mathoulin-Pélissier S, Blay JY, GSF-GETO French Sarcoma Group. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2012 Mar:23(3):777-784. doi: 10.1093/annonc/mdr282. Epub 2011 Jun 7
[PubMed PMID: 21652583]
Level 1 (high-level) evidence
[55]
Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PC, Verweij J, Blay JY. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). European journal of cancer (Oxford, England : 1990). 2010 Jan:46(1):72-83. doi: 10.1016/j.ejca.2009.09.022. Epub
[PubMed PMID: 19853437]
Level 2 (mid-level) evidence
[56]
Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Mar 10:34(8):786-93. doi: 10.1200/JCO.2015.62.4734. Epub 2015 Sep 14
[PubMed PMID: 26371143]
Level 1 (high-level) evidence
[57]
Le Cesne A, Blay JY, Domont J, Tresch-Bruneel E, Chevreau C, Bertucci F, Delcambre C, Saada-Bouzid E, Piperno-Neumann S, Bay JO, Mir O, Ray-Coquard I, Ryckewaert T, Valentin T, Isambert N, Italiano A, Clisant S, Penel N. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. The Lancet. Oncology. 2015 Mar:16(3):312-9. doi: 10.1016/S1470-2045(15)70031-8. Epub 2015 Feb 11
[PubMed PMID: 25680558]
Level 1 (high-level) evidence
[58]
Vo KT, Matthay KK, DuBois SG. Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Clinical sarcoma research. 2016:6():9. doi: 10.1186/s13569-016-0049-z. Epub 2016 Jun 7
[PubMed PMID: 27274393]
[59]
van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P, EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2012 May 19:379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012 May 16
[PubMed PMID: 22595799]
Level 1 (high-level) evidence
[60]
Lee ATJ, Jones RL, Huang PH. Pazopanib in advanced soft tissue sarcomas. Signal transduction and targeted therapy. 2019:4():16. doi: 10.1038/s41392-019-0049-6. Epub 2019 May 17
[PubMed PMID: 31123606]
[61]
Deguchi S, Mitsuya K, Nakasu Y, Hayashi N, Katagiri H, Murata H, Wasa J, Takahashi M, Endo M. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature. Investigational new drugs. 2018 Apr:36(2):346-349. doi: 10.1007/s10637-017-0521-5. Epub 2017 Oct 25
[PubMed PMID: 29067537]
Level 3 (low-level) evidence
[62]
McBride A, Butler SK. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2012 May 1:69(9):745-55. doi: 10.2146/ajhp110237. Epub
[PubMed PMID: 22517020]
[63]
Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet (London, England). 2016 Apr 16:387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. Epub 2016 Feb 10
[PubMed PMID: 26874885]
Level 1 (high-level) evidence
[64]
Blay JY, Schöffski P, Bauer S, Krarup-Hansen A, Benson C, D'Adamo DR, Jia Y, Maki RG. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. British journal of cancer. 2019 May:120(11):1026-1032. doi: 10.1038/s41416-019-0462-1. Epub 2019 May 8
[PubMed PMID: 31065111]
Level 1 (high-level) evidence
[65]
D'Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. The Lancet. Oncology. 2018 Mar:19(3):416-426. doi: 10.1016/S1470-2045(18)30006-8. Epub 2018 Jan 19
[PubMed PMID: 29370992]
Level 2 (mid-level) evidence
[66]
Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Oct 1:20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8
[PubMed PMID: 24714771]
[67]
Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jul 1:25(13):3753-3758. doi: 10.1158/1078-0432.CCR-18-4070. Epub 2019 Feb 20
[PubMed PMID: 30787022]
[68]
Liu D, Offin M, Harnicar S, Li BT, Drilon A. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Therapeutics and clinical risk management. 2018:14():1247-1252. doi: 10.2147/TCRM.S147381. Epub 2018 Jul 20
[PubMed PMID: 30050303]
[69]
García-Del-Muro X, López-Pousa A, Maurel J, Martín J, Martínez-Trufero J, Casado A, Gómez-España A, Fra J, Cruz J, Poveda A, Meana A, Pericay C, Cubedo R, Rubió J, De Juan A, Laínez N, Carrasco JA, de Andrés R, Buesa JM, Spanish Group for Research on Sarcomas. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jun 20:29(18):2528-33. doi: 10.1200/JCO.2010.33.6107. Epub 2011 May 23
[PubMed PMID: 21606430]
Level 1 (high-level) evidence
[70]
D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Hensley ML, Hirst CM, Ezeoke MO, Ahn L, Qin LX, Antonescu CR, Lefkowitz RA, Maki RG, Schwartz GK, Tap WD. A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. The oncologist. 2019 Jun:24(6):857-863. doi: 10.1634/theoncologist.2018-0160. Epub 2018 Aug 20
[PubMed PMID: 30126857]
Level 2 (mid-level) evidence
[71]
Ansari L, Shiehzadeh F, Taherzadeh Z, Nikoofal-Sahlabadi S, Momtazi-Borojeni AA, Sahebkar A, Eslami S. The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials. Cancer gene therapy. 2017 May:24(5):189-193. doi: 10.1038/cgt.2017.9. Epub 2017 Apr 14
[PubMed PMID: 28409561]
Level 1 (high-level) evidence
[72]
Grenader T, Goldberg A, Hadas-Halperin I, Gabizon A. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas. Anti-cancer drugs. 2009 Jan:20(1):15-20. doi: 10.1097/CAD.0b013e3283198058. Epub
[PubMed PMID: 19342997]
[73]
Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, van Oosterom AT, Clemons MJ, Kamby C, Hermans C, Whittaker J, Donato di Paola E, Verweij J, Nielsen S. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. European journal of cancer (Oxford, England : 1990). 2001 May:37(7):870-7
[PubMed PMID: 11313175]
Level 1 (high-level) evidence
[74]
O'Cearbhaill R, Zhou Q, Iasonos A, Soslow RA, Leitao MM, Aghajanian C, Hensley ML. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecologic oncology. 2010 Mar:116(3):424-9. doi: 10.1016/j.ygyno.2009.10.064. Epub 2009 Nov 24
[PubMed PMID: 19932916]
[75]
Thanopoulou E, Thway K, Khabra K, Judson I. Treatment of hormone positive uterine leiomyosarcoma with aromatase inhibitors. Clinical sarcoma research. 2014:4():5. doi: 10.1186/2045-3329-4-5. Epub 2014 Jun 26
[PubMed PMID: 25018868]
[76]
Cates JMM. The AJCC 8th Edition Staging System for Soft Tissue Sarcoma of the Extremities or Trunk: A Cohort Study of the SEER Database. Journal of the National Comprehensive Cancer Network : JNCCN. 2018 Feb:16(2):144-152. doi: 10.6004/jnccn.2017.7042. Epub
[PubMed PMID: 29439175]
[77]
Hahn E, Huang SH, Hosni A, Razak AA, Jones RL, Dickson BC, Sturgis EM, Patel SG, O'Sullivan B. Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck. Clinical and translational radiation oncology. 2019 Feb:15():13-19. doi: 10.1016/j.ctro.2018.11.009. Epub 2018 Nov 27
[PubMed PMID: 30582016]
[78]
Tanaka K, Tsumura H. Eighth edition of the American Joint Committee on Cancer staging system for soft tissue sarcoma of the trunk and extremity: in search of a better staging system. Annals of translational medicine. 2019 Mar:7(Suppl 1):S11. doi: 10.21037/atm.2019.01.31. Epub
[PubMed PMID: 31032292]
[79]
Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchère D, Sastre X, Vilain MO, Bonichon F, N'Guyen Bui B. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001 May 15:91(10):1914-26
[PubMed PMID: 11346874]
[80]
Lu YJ, Wang H, Fang LY, Wang WJ, Song W, Wang Y, Huang YQ, Din ZL. A nomogram for predicting overall survival in patients with uterine leiomyosarcoma: a SEER population-based study. Future oncology (London, England). 2020 Apr:16(10):573-584. doi: 10.2217/fon-2019-0674. Epub 2020 Mar 6
[PubMed PMID: 32141309]
[81]
Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 May:14(5):1679-89
[PubMed PMID: 8622088]
[82]
Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, Evans HL. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003 May 15:97(10):2530-43
[PubMed PMID: 12733153]
[83]
D'Angelo E, Espinosa I, Ali R, Gilks CB, Rijn Mv, Lee CH, Prat J. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. Gynecologic oncology. 2011 May 1:121(2):328-33. doi: 10.1016/j.ygyno.2011.01.022. Epub 2011 Feb 12
[PubMed PMID: 21316747]
[84]
Maki RG, Moraco N, Antonescu CR, Hameed M, Pinkhasik A, Singer S, Brennan MF. Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7. Annals of surgical oncology. 2013 Oct:20(11):3377-83. doi: 10.1245/s10434-013-3052-0. Epub 2013 Jun 18
[PubMed PMID: 23775410]
[85]
Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Annals of surgery. 2014 Sep:260(3):416-21; discussion 421-2. doi: 10.1097/SLA.0000000000000869. Epub
[PubMed PMID: 25115417]
[86]
Zivanovic O, Jacks LM, Iasonos A, Leitao MM Jr, Soslow RA, Veras E, Chi DS, Abu-Rustum NR, Barakat RR, Brennan MF, Hensley ML. A nomogram to predict postresection 5-year overall survival for patients with uterine leiomyosarcoma. Cancer. 2012 Feb 1:118(3):660-9. doi: 10.1002/cncr.26333. Epub 2011 Jul 12
[PubMed PMID: 21751199]
[87]
Lindner LH, Litière S, Sleijfer S, Benson C, Italiano A, Kasper B, Messiou C, Gelderblom H, Wardelmann E, Le Cesne A, Blay JY, Marreaud S, Hindi N, Desar IME, Gronchi A, van der Graaf WTA. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). International journal of cancer. 2018 Jun 15:142(12):2610-2620. doi: 10.1002/ijc.31286. Epub 2018 Feb 14
[PubMed PMID: 29383713]
Level 2 (mid-level) evidence